Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

International Journal of Cancer

Volumn 133, Issue 3, 2013, Pages 624-636

  Hodge, James W ^a   Garnett, Charlie T ^a,c   Farsaci, Benedetto ^a   Palena, Claudia ^a   Tsang, Kwong Yok ^a   Ferrone, Soldano ^b,d   Gameiro, Sofia R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

antigen processing machinery; calreticulin; docetaxel; immunogenic cell death; immunogenic modulation; T cell response

Indexed keywords

CALRETICULIN; CARCINOEMBRYONIC ANTIGEN; CD133 ANTIGEN; DOCETAXEL; FAS LIGAND; HIGH MOBILITY GROUP B1 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOXANTRONE; MUCIN 1; MULTIDRUG RESISTANCE PROTEIN 1; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PURINERGIC P2X7 RECEPTOR; TAPASIN; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL DEATH; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; TUMOR CELL;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CALRETICULIN; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EIF-2 KINASE; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNOTHERAPY; MALE; MUCIN-1; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TAXOIDS;

EID: 84878016733     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28070     Document Type: Article

References (50)

1. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004; 64: 7985-94.
2. Garnett CT, Schlom J, Hodge JW,. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008; 14: 3536-44.
3. Seliger B, Maeurer MJ, Ferrone S,. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 455-64.
4. Bandoh N, Ogino T, Cho HS, et al. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005; 66: 185-94.
5. Ogino T, Wang X, Ferrone S,. Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods 2003; 278: 33-44.
6. Muraro R, Wunderlich D, Thor A, et al. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 1985; 45: 5769-80.
7. Tsang KY, Palena C, Gulley J, et al. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 2004; 10: 2139-49.
8. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87: 982-90.
9. Tsang KY, Zhu M, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997; 3: 2439-49.
10. Gelbard A, Garnett CT, Abrams SI, et al. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 2006; 12: 1897-905.
11. Brown I, Shalli K, McDonald SL, et al. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res 2004; 6: R601-7.
12. Martins I, Tesniere A, Kepp O, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8: 3723-8.
13. Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30: 61-9.
14. Locher C, Conforti R, Aymeric L, et al. Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 2010; 1209: 99-108.
15. Martins I, Kepp O, Galluzzi L, et al. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci 2011; 1209: 77-82.
16. Zitvogel L, Kepp O, Senovilla L, et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16: 3100-4.
17. Panis C, Lemos LG, Victorino VJ, et al. Immunological effects of taxol and adryamicin in breast cancer patients. Cancer Immunol Immunother 2012; 61: 481-8.
18. Fojo AT, Menefee M,. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32: S3-8.
19. Komarova NL, Wodarz D,. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A 2005; 102: 9714-9.
20. Kawamoto H, Yuasa T, Kubota Y, et al. Characteristics of CD133(+) human colon cancer SW620 cells. Cell Transplant 2010; 19: 857-64.
21. Leibowitz MS, Andrade Filho PA, Ferrone S, et al. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother 2011; 60: 525-35.
22. Lopez-Albaitero A, Nayak JV, Ogino T, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006; 176: 3402-9.
23. Setiadi AF, Omilusik K, David MD, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 2008; 68: 9601-7.
24. Panaretakis T, Kepp O, Brockmeier U, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578-90.
25. Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15: 1499-509.
26. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2: 63ra94.
27. Hannani D, Sistigu A, Kepp O, et al. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 2011; 17: 351-8.
28. Martins I, Kepp O, Schlemmer F, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-58.
29. Zitvogel L, Kepp O, Kroemer G,. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151-60.
30. Vacchelli E, Galluzzi L, Fridman WH, et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1: 179-88.
31. Gameiro SR, Caballero JA, Higgins JP, et al. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 2011; 60: 1227-42.
32. Chan OT, Yang LX,. The immunological effects of taxanes. Cancer Immunol Immunother 2000; 49: 181-5.
33. Eckert K, Fuhrmann-Selter T, Maurer HR,. Docetaxel enhances the expression of E-cadherin and carcinoembryonic antigen (CEA) on human colon cancer cell lines in vitro. Anticancer Res 1997; 17: 7-12.
34. Matsuzaki I, Suzuki H, Kitamura M, et al. Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology 2000; 59: 336-43.
35. Prete SP, Aquino A, Masci G, et al. Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effect of 5-fluorouracil. J Pharmacol Exp Ther 1996; 279: 1574-81.
36. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-701.
37. Pradeu T, Carosella ED,. On the definition of a criterion of immunogenicity. Proc Natl Acad Sci U S A 2006; 103: 17858-61.
38. Minami H, Kawada K, Sasaki Y, et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci 2009; 100: 144-9.
39. Morse DL, Gray H, Payne CM, et al. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005; 4: 1495-504.
40. Luo B, Lee AS,. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 2012 Apr 16 [Epub ahead of print].
41. Huerta S, Heinzerling JH, Anguiano-Hernandez YM, et al. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res 2007; 142: 184-94.
42. Shtil AA, Turner JG, Durfee J, et al. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 1999; 93: 1831-7.
43. Racanelli V, Leone P, Frassanito MA, et al. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood 2011; 115: 1185-93.
44. Seliger B, Stoehr R, Handke D, et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 2010; 59: 529-40.
45. Fu H, Liu C, Flutter B, et al. Calreticulin maintains the low threshold of peptide required for efficient antigen presentation. Mol Immunol 2009; 46: 3198-206.
46. Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-79.
47. Li SS, Liu Z, Uzunel M, et al. Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. Blood 2006; 108: 3112-20.
48. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1260-9.
49. Petrylak D,. Defining the optimal role of immunotherapy and chemotherapy: advanced prostate cancer patients who recieve sipuleucel-T (PROVENGE) followed by docetaxel derive greatest survivial benefit. 14th Annual Meeting of the Chemotherapy Foundation Symposium, 2006.
50. Schlom J, Gulley JL, Arlen PM,. Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) 2008; 233: 522-34.